Abstract Book - PDF - San Antonio Breast Cancer Symposium

CTRC-AACR San Antonio Breast Cancer Symposium
P3-10-03 Bartonella henselae Infection Detected in Patients with
Inflammatory Breast Cancer
Fernandez SV, Aburto L, Maggi R, Breitschwerdt EB, Cristofanilli M.
Fox Chase Cancer Center, Philadelphia, PA; North Caroline State
University, Raleigh, NC.
P3-10-04 Regulation of inflammatory breast cancer cell invasion
through Akt1/PKBα phosphorylation of RhoC GTPase
Lehman HL, Van Laere SJ, van Golen CM, Vermeulen PB, Dirix LY, van
Golen KL. The University of Delaware, Newark, DE; Sint Augustine
Hospital, Antwerp, Belgium; Catholic University, Leuven, Belgium;
Delaware State University, Dover, DE.
P3-10-05 Response to neoadjuvant systemic therapy (NST) in
inflammatory breast cancer (IBC) according to estrogen
receptor (ER) and HER2 expression
Masuda H, Iwamoto T, Brewer T, Hsu L, Kai K, Woodward WA,
Reuben JM, Valero V, Alvarez RH, Willey J, Hortobagyi GN, Ueno NT.
Morgan Welch Inflammatory Breast Cancer Research Program and
Clinic, The University of Texas MD Anderson Cancer Center, Houston,
TX; The University of Texas MD Anderson Cancer Center, Houston,
TX; Okayama University Hospital, Okayama, Japan.
P3-10-06 Patterns of failure in patients with inflammatory breast
cancer: the case for aggressive local/regional treatment
Warren LE, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-
Bartek J, Overmoyer BA, Bellon JR. Harvard Medical School, Boston,
MA; Dana Farber Cancer Institute, Harvard Medical School,
Boston, MA.
P3-10-07 Lymph node status and survival in inflammatory breast cancer
Sieffert MR, Pedersen RC, Tereffe W, Cui H, Woods RR, Viscusi RK,
LeBeau-Grasso L, Lang JE. University of Arizona College of Medicine,
Tucson, AZ; University of Texas MD Anderson Cancer Center,
Houston, TX; University of Arizona Cancer Center, Tucson, AZ;
University of Arizona Health Sciences Center, Tucson, AZ; University
of Southern California Norris Comprehensive Cancer Center, Los
Angeles, CA.
P3-10-08 A new in vitro method of growing and studying inflammatory
breast cancer emboli
Lehman HL, Daasner EJ, Vermeulen PB, Dirix LY, Van Laere S, van
Golen KL. The University of Delaware, Newark, DE; Sint Augustine
Hospital, Antwerp, Belgium; Catholic University, Leuven, Belgium.
P3-10-09 Peptide-based molecular targeting of inflammatory
breast cancer
Eckhardt BL, Miao RY, Cao Y, Driessen WH, Krishnamurthy S,
Arap W, Ueno N, Anderson RL, Pasqualini R. The University of Texas
at MD Anderson Cancer Center, Houston, TX; Stanford University
School of Medicine; Trescowthick Research Laboratories, Peter
MacCallum Cancer Center; The University of Texas at MD Anderson
Cancer Center.
P3-10-10 Status of anaplastic lymphoma kinase (ALK) gene in
inflammatory breast carcinoma
Krishnamurthy S, Woodward W, Reuben JM, Tepperberg J, Ogura
D, Niwa S, Ueno NT. MD Anderson Cancer Center, Houston, TX;
LabCorp, Durham, NC; Link Genomics, Toyoka, Japan
Treatment: Male Breast Cancer
P3-11-01 Matched-pair analysis of patients with male and female
breast cancer
Kim M, Lee SK, Choi M-Y, Kim S, Kim J, Jung SP, Bae SY, Kil WH, Lee
JE, Nam SJ. Samsung Medical Center, Sungkyunkwan University
School of Medicine, Seoul, Republic of Korea.
P3-11-02 Male breast cancer: A comparison between BRCA mutation
carriers and non-carriers in Hong Kong, Southern China
Kwong A, Chau WW, Wong CHN, Law FBF, Ng EKO, Suen DTK, Kurian
AW, West DW, Ford JM, Ma ESK. University of Hong Kong, Pokfulam,
Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry,
Happy Valley, Hong Kong; Stanford University School of Medicine,
Stanford, CA; Hong Kong Sanitorium & Hospital, Happy Valley,
Hong Kong.
P3-11-03 Treatment outcomes for early stage male breast cancer: a
single centre retrospective case-control study
Kwong A, Visram H, Graham N, Balchin K, Petrcich W, Dent S. The
Ottawa Hospital, Ottawa, ON, Canada; Ottawa Hospital Research
Institute, Ottawa, ON, Canada.
P3-11-04 Male breast cancer: Overall survival in a single institution
Bello MA, Bergmann A, Costa CRA, Pinto RR, Millen EC,
Thuler LCS, Bender PFM. Brazilian National Cancer Institute,
Rio de Janeiro, Brazil.
Treatment: Brain Metastases
P3-12-01 Serum biomarkers identification using quantitative
proteomics in patients (pts) with untreated brain metastases
from HER2-positive breast cancer receiving capecitabine (C)
and lapatinib (L) (UNICANCER LANDsCAPE trial)
Gonçalves A, Camoin L, Ben Younès I, Romieu G, Campone M, Diéras
V, Cropet C, Mahier Aït-Oukhatar C, Dalenc F, Le Rhun E, Labbe-
Devilliers C, Borg J-P, Bachelot T. Institut Paoli Calmettes, Marseille,
France; Université de la Méditerranée, Marseille, France; Centre Val
d’Aurelle, Montpellier, France; Institut de Cancérologie de l’Ouest,
Nantes, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon,
France; Unicancer, Paris, France; Institut Claudius Regaud, Toulouse,
France; Centre Oscar Lambret, Lille, France.
P3-12-02 The impact of estrogen receptor status on treatment
outcomes following gamma knife radiosurgery for brain
metastases of primary breast cancer
Cupelo EC, Aridgides PD, Bogart JA, Hahn SS, Shapiro AJ. SUNY
Upstate Medical University, Syracuse, NY.
P3-12-03 Combined targeting of HER2 and VEGFR2 for effective
treatment of HER2-amplified breast cancer brain metastases
Kodack DP, Chung E, Yamashita H, Incio J, Peters A, Song Y, Ager E,
Huang Y, Farrar C, Lussiez A, Goel S, Snuderl M, Kamoun W, Hiddingh
L, Tannous BA, Fukumura D, Engelman JA, Jain RK. Massachusetts
General Hospital, Boston, MA.
P3-12-04 A phase 2, multi-center, open label study evaluating the
efficacy and safety of GRN1005 alone or in combination with
trastuzumab in patients with brain metastases from breast
cancer
Lin NU, Schwartzberg LS, Kesari S, Yardley DA, Verma S, Anders CK,
Shih T, Shen Y, Miller K. UC San Diego, La Jolla, CA; Indiana University
Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sunnybrook
Odette Cancer Centre, Toronto, ON, Canada; Dana-Farber Cancer
Institute, Boston, MA; The West Clinic, Memphis, TN; Geron, Menlo
Park, CA; University of North Carolina at Chapel Hill, NC; Sarah
Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC.,
Nashville, TN.
P3-12-05 Clinical features and outcomes of leptomeningeal metastasis
in patients with breast cancer: a single center experience
Jo J-C, Kang MJ, Ahn J-H, Jung KH, Kim JE, Gong G, Kim HH, Ahn SD,
Kim SS, Son BH, Ahn SH, Kim S-B. Asan Medical Center, University of
Ulsan College of Medicine, Seoul, Korea.
P3-12-06 Clinicopathological Analysis of Breast Cancer Patients with
Brain Metastases
Ushio A, Sawaki M, Fujita T, Hattori M, Kondo N, Horio A, Gondou N,
Iwata H. Aichi Cancer Center, Japan.
Cancer Res; 72(24 Suppl.) December 15, 2012 40s Cancer Research